Table 4.

ALK-positive patients with acquired crizotinib resistance

PatientTiming (months)aDuration (months)bALK fusionALK amplificationALK secondary mutationEGFR mutationKRAS mutation
MGH0NZ020PositiveNoNoWTWT
MGH0014.54PositiveNoNoWTWT
MGH01008PositiveNoNoWTWT
MGH011034PositiveNoS1206YWTWT
MGH01309PositiveNoNoWTWT
MGH01666PositiveNoNoWTWT
MGH017023+PositiveNoNoWTWT
MGH0180.510PositiveNoG1202RN/AN/A
MGH019<0.58PositiveNoNoWTWT
MGH020013N/AN/AL1196MN/AN/A
MGH021312PositiveNo1151Tins, G1269AWTWT
MGH02206PositiveNoNoWTWT
MGH023012PositiveNoNoWTWT
MGH024015PositiveNoNoN/AN/A
MGH025011N/AN/ANoWTWT
MGH02714N/AN/ANoN/AN/A
MGH028114N/AN/ANoN/AN/A
MGH02908PositiveYesNoN/AN/A
MGH03009PositiveNoNoWTWT
MGH031N/AN/APositiveNoNoWTWT
MGH032219PositiveNoNoN/AN/A
MGH03303PositiveNoNoWTWT
MGH03408PositiveYesNoWTWT
MGH035N/A14PositiveNoNoWTWT
MGH0360.513PositiveNoNoWTWT
MGH037011PositiveNoG1269AWTWT
MGH03807PositiveNoL1196MWTWT
MGH04009PositiveNoNoWTWT
MGH04405PositiveYescNoWTWT
MGH045013PositiveNoL1196MN/AN/A
MGH051<0.53PositiveNoNoWTWT
MGH0548.53PositiveNoNoWTWT
MGH05503N/AN/ANoN/AN/A
MGH058014PositiveNoNoWTWT
  • aIndicates the time interval between last crizotinib dose and repeat biopsy. Repeat biopsies conducted while the patient is still receiving crizotinib are depicted with a “0”.

  • bIndicates the approximate duration the patient was treated with crizotinib.

  • cLow level ALK amplification.